✦ LIBER ✦

Abciximab or Eptifibatide in Percutaneous Coronary Intervention: In-Hospital Outcomes and Costs and Six-Month Results

✍ Scribed by Brett C. Burgess; Shafik Hanna-Moussa; Kala Ramasamy; Diana Sigler; Shukri David

Book ID: 106186443
Publisher: Springer
Year: 2011
Tongue: English
Weight: 76 KB
Volume: 11
Category: Article
ISSN: 1061-1711
DOI: 10.1007/s00547-002-0927-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute procedural complications and in-ho

Acute procedural complications and in-hospital events after percutaneous coronary interventions: Eptifibatide versus Abciximab

✍ Andrew E. Ajani; Ron Waksman; Luis Gruberg; Arvind K. Sharma; Robert Lew; Ellen 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Evaluation of the role of abciximab (Reo

Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: In-hospital and six-month outcomes

✍ James L. Velianou; Bradley H. Strauss; Catherine Kreatsoulas; Danny Pericak; Mad 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Meta-analysis of effectiveness and safet

Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention

✍ David L Brown; Cathy S.J Fann; Chee Jen Chang 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Impact of bivalirudin on in-hospital ble

Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention

✍ Gilles Lemesle; Axel De Labriolle; Laurent Bonello; Asmir Syed; Sara Collins; Ga 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

Eptifibatide Is Noninferior to Abciximab

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention: Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

✍ Axel Åkerblom; Stefan K. James; Michail Koutouzis; Bo Lagerqvist; Ulf Stenestran 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 480 KB

Incidence and time course of thrombocyto

Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention

✍ Ibrahim E. Fahdi; Jorge F. Saucedo; Thomas Hennebry; Mohammad Ghani; Saihari Sad 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 94 KB